0001127602-18-015838.txt : 20180501
0001127602-18-015838.hdr.sgml : 20180501
20180501190733
ACCESSION NUMBER: 0001127602-18-015838
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180427
FILED AS OF DATE: 20180501
DATE AS OF CHANGE: 20180501
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Harper Sean E
CENTRAL INDEX KEY: 0001541946
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37702
FILM NUMBER: 18797101
MAIL ADDRESS:
STREET 1: AMGEN INC.
STREET 2: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320-1799
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMGEN INC
CENTRAL INDEX KEY: 0000318154
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 953540776
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
BUSINESS PHONE: (805)447-1000
MAIL ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
FORMER COMPANY:
FORMER CONFORMED NAME: AMGEN
DATE OF NAME CHANGE: 19870305
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2018-04-27
0000318154
AMGEN INC
AMGN
0001541946
Harper Sean E
ONE AMGEN CENTER DRIVE
THOUSAND OAKS
CA
91320-1799
1
EVP, Research & Development
Common Stock
2018-04-27
4
A
0
4508
0
A
61296
D
Nqso (Right to Buy)
177.46
2018-04-27
4
A
0
34702
0
A
2020-04-27
2028-04-27
Common Stock
34702
34702
D
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 4/27/2020, 4/27/2021 and 4/27/2022, respectively.
These shares include the following RSUs granted under the Company's equity plans: 1,340 RSUs which vest in one installment on 1/30/2019; 4,477 RSUs which vest in two equal installments of 1,477 on 5/3/2018 and 5/3/2019 and one installment of 1,523 on 5/3/2020; and 4,551 RSUs which vest in installments of 1,501 on 5/1/2019, 1,502 on 5/1/2029 and 1,548 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
These shares include 477 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/27/2020, 4/27/2021 and 4/27/2022, respectively.
/s/ Andrea A. Robinson, Attorney-in-Fact for Dr. Harper
2018-05-01